Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM
Anna Stanhewicz, PhD · NCT06547619
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–50 · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Early Phase 1
- Target enrollment
- 40
- US sites recruiting
- 1
- Study start
- October 1, 2024
- Record last updated
- July 29, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Women with a history of gestational diabetes mellitus (GDM) are at a 2-fold greater risk for the development of overt cardiovascular disease (CVD) following the effected pregnancy. While subsequent development of type II diabetes elevates this risk, prior GDM is an independent risk factor for CVD morbidity, particularly, within the first decade postpartum. GDM is associated with impaired endothelial function during pregnancy and decrements in macro- and microvascular function persist postpartum, despite the remission of insulin resistance following delivery. Collectively, while the association between GDM and elevated lifetime CVD risk is clear, and available evidence demonstrates a link between GDM and vascular dysfunction in the decade following pregnancy, the mechanisms mediating this persistent dysfunction remain unexamined.
The purpose of this investigation is to examine the role of endothelin-1, a potent vasoconstrictor, in aberrant microvascular function in otherwise healthy women with a history of GDM and to identify whether this mechanism is influenced by physical activity and sedentary behavior.
Being studied: Insulin aspart
Conditions: Gestational Diabetes; Endothelial Dysfunction; Physical Inactivity
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
INCLUSION CRITERIA
- history of pregnancy within 5 years of the study visit
- had healthy pregnancy OR had gestational diabetes diagnosed by their obstetrician and confirmed according to the American College of Obstetricians and Gynecologists criteria for gestational diabetes.
EXCLUSION CRITERIA
- skin diseases,
- current tobacco or electronic cigarette/vape pen use,
- diagnosed or suspected hepatic or metabolic disease including diabetes,
- statin or other cholesterol-lowering medication,
- current antihypertensive medication,
- history of preeclampsia or gestational hypertension
- current hypertension,
- current pregnancy,
- body mass index \<18.5 kg/m2,
- allergy to materials used during the experiment.(e.g. latex), known allergies to study drugs.
Recruiting US locations
University of Iowa
Iowa City, IA 52242
Site contact: Anna Stanhewicz, PhD · 319-467-1732 · anna-stanhewicz@uiowa.edu
Study contacts (from the official record)
- Anna Reid-Stanhewicz, PHD · 319-467-1732 · anna-stanhewicz@uiowa.edu
Similar studies in Iowa
All diabetes studies in Iowa →- RecruitingHealthy volunteersEarly Phase 1
Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes
Anna Stanhewicz, PhD
- Location
- Iowa City, IA
- Eligibility basics
- Ages 18–50 · Women only
- RecruitingHealthy volunteersPhase 1
The Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy
Anna Stanhewicz, PhD
- Location
- Iowa City, IA
- Eligibility basics
- Ages 18–50 · Women only
- RecruitingHealthy volunteersEarly Phase 1
Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
Anna Stanhewicz, PhD
- Location
- Iowa City, IA
- Eligibility basics
- Ages 18–45 · Women only
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Des Moines, IA + 55 other US sites
- Eligibility basics
- Ages 18–79